Epilepsy Incidence Among Children in the United States
Closed Posted
- Opportunity number
- RFA-DP-25-038
- Agency
-
Centers for Disease Control and Prevention
Department of Health and Human Services
- Applications due
- Award size
- Up to $500,000
Opportunity facts
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Category
-
- Health
- Eligible applicants
-
- Tribal Organizations (Not Federally Recognized)
- For Profit Organizations
- County Governments
- Higher Education Inst. (Public)
- Tribal Governments (Federally Recognized)
- State Governments
- Independent School Districts
- 501(c)(3) Nonprofits
- Public or Indian Housing Auth.
- Small Businesses
- City/Township Governments
- Higher Education Inst. (Private)
- Special District Governments
- Full announcement
Opportunity details come from Grants.gov. Updated .
About this opportunity
The Centers for Disease Control and Prevention (CDC) is seeking applications for a $1.6 million cooperative agreement to study epilepsy incidence among children aged 0-17 in the United States. The research objectives are to: (1) estimate overall epilepsy incidence rates; (2) examine disparities in incidence stratified by demographics and social determinants of health; and (3) identify risk factors associated with developing epilepsy. Eligible applicants include state/local governments, tribal organizations, universities, nonprofits, and for-profit organizations. Proposals must use comprehensive nationwide or population-based datasets to yield nationally representative findings and include a multidisciplinary research team with expertise in epidemiologic methods, population studies, and pediatric epilepsy.
The anticipated award is for one cooperative agreement, with $500,000 available for the first budget period of September 2025 to September 2029. Applicants must submit a letter of intent by December 12, 2024 and the full application by January 23, 2025. Awards will be made based on a scientific merit review process, with the estimated start date of September 30, 2025.
Synopsis
Few population-based epilepsy incidence studies among children in the United States exist, and these studies are limited to specific geographic areas with small sample sizes. Studies which used nationwide administrative and claims data to estimate epilepsy incidence among children were conducted more than a decade ago and failed to provide national generalizability due to their limited data sources. This NOFO will contribute to a comprehensive understanding of epilepsy incidence (any type), incident-related risk factors, and incidence disparities among the general U.S. pediatric population or subpopulations. The knowledge obtained from this study will assist health officials shape public health policies by allocating resources, planning for healthcare services, and implementing preventive measures. The objectives of the NOFO are to: (1) Estimate epilepsy incidence among U.S. children 0 - 17 years of age based upon a study with comprehensive nationwide dataset(s), or a population-based study at a specific level(s) (e.g., national, regional, jurisdictional); (2) Identify factors that contribute to the risk of developing epilepsy, and examine the association between these risk factors and incidence; and (3) Examine potential disparities in incidence rates of epilepsy stratified by demographic, geographical, the social determinants of health (SDOH), or other characteristics. The target population is for U.S. children aged 0 - 17 years, and for the study of certain epilepsies, some age ranges within 0 - 17 years are acceptable. Additionally, this study should include a nationally representative sample of age, sex, race/ethnicity, and social strata, and include subgroups which allow an examination of risk factors and SDOH. The applicant is expected to: (1) Conduct a retrospective study using public/commercial administrative and/or claims data, electronic health records, or survey data; (2) Ensure dataset(s) have sufficient sample sizes relative to risk factors, allowing incidence rates to be stratified by these factors. If public/commercial claims data or survey data are used, it should include child populations from all states and Washington DC. Examples of claims data are Marketscan and Medicaid. If EHR data are used, adequate details/justification must be included; (3) Identify risk factors based on the literature. Risk factors may be children-specific (e.g., prenatal, perinatal, or neonatal factors), children non-specific (e.g., comorbidities, demographic, SDOH factors), and/or other factors; and (4) Propose a research team with expertise in epidemiological methods, analytical skills, and pediatric epilepsy diagnosis and treatment.
Files
| File | Type | Posted |
|---|---|---|
| RFA-DP-25-038 Question and Answer Document. Final. V2.pdf | ||
| RFA-DP-25-038_20241220.pdf | ||
| RFA-DP-25-038_20241106.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity